What kind of company is Ilumya?

Overview of IlumyaIlumya is a brand name for tildrakizumab-asmn, an interleukin-23 antagonist used to treat plaque psoriasis. It is developed and marketed by Sun Pharmaceutical Industries, an Indian multinational pharmaceutical company.

Approval and AvailabilityIlumya was approved by the United States Food and Drug Administration (FDA) for the treatment of moderate to severe plaque psoriasis in March 2018. It is available as an injection for subcutaneous use in vials and prefilled syringes. Ilumya is also available in several other countries, including Canada and Japan.

Usage and EffectivenessIlumya is used to treat psoriasis, a chronic skin condition that causes red, scaly patches on the skin. Ilumya works by blocking the action of interleukin-23, a protein that plays a key role in the development of psoriasis. Clinical studies have shown that Ilumya is effective in reducing the severity of psoriasis symptoms and improving patients' quality of life.

Company ProfileSun Pharmaceutical Industries is a multinational pharmaceutical company headquartered in Mumbai, India. It was founded in 1983 and is currently the largest pharmaceutical company in India and the fifth largest specialty generic pharmaceutical company in the world. Sun Pharma specializes in the development and manufacture of pharmaceutical formulations, active pharmaceutical ingredients (API), and drug delivery systems. It is also involved in research and development, and has a number of drugs in various stages of clinical development. The company has a global presence, with operations in over 150 countries, and employs approximately 34,000 people worldwide. In addition to Ilumya, Sun Pharma's product portfolio includes drugs for a wide range of therapeutic areas, including cardiology, gastroenterology, and neurology.